Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Intranasal Midazolam as First Line Treatment for Status Epilepticus

Key clinical point: When a patient in status epilepticus doesn’t already have an intravenous line in place, alternative routes of benzodiazepine administration become more attractive.

Major finding: About 57% of patients experienced cessation of their status epilepticus an average of 5 minutes after receiving intranasal midazolam.

Study details: This was a prospective, observational study of 42 patients who received intranasal midazolam as first-line treatment for their status epilepticus.

Disclosures: The presenter reported having no financial conflicts regarding her study, conducted free of commercial support.

Citation:

Kay L et al. IEC 2019, Abstract P029.